Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial

被引:8
作者
Zhou, Jing [1 ]
Yang, Dong [1 ]
Zhou, Shu-hong [1 ]
Wang, Jin-ping [1 ]
Liu, Yue-shu [2 ]
Wang, Shu-lan [1 ]
机构
[1] Gansu Prov Hosp, Dept Immunol & Rheumatol, Lanzhou 730000, Peoples R China
[2] Gansu Prov Hosp, Dept Tradit Chinese Med, Lanzhou 730000, Peoples R China
关键词
Chinese medicine; bathing therapy; systemic sclerosis; treatment efficacy; adverse effects; QUALITY-OF-LIFE; QUESTIONNAIRE-DISABILITY INDEX; DOUBLE-BLIND; SCLERODERMA; CLASSIFICATION; CRITERIA; COHORT; SCORE;
D O I
10.1007/s11655-017-2954-2
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
To examine the efficacy and safety of bathing therapy with Taohong Siwu Decoction (TSD) in the treatment of early-stage, mild-moderate diffuse cutaneous systemic sclerosis (dcSSc). This randomized, placebo-controlled trial enrolled 148 men and women (18-60 years) with dcSSc (disease duration 12 months) and baseline modified Rodnan skin score (MRSS) 10. Patients were randomized into a TSD group (71 cases bathing with TSD plus oral prednisone) or control group (71 cases bathing with placebo plus oral prednisone). Bathing (40 A degrees C, 30 min) of the upper and lower limbs was carried out once daily for 12 consecutive weeks. The primary outcome measure was MRSS; secondary outcomes were Raynaud's phenomenon (RP) score, quality of life (QOL), physician visual analogue scale (VAS), patient VAS, percent predicted diffusing capacity for carbon monoxide (DLCO), percent predicted forced vital capacity (FVC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level and overall treatment effect. The final analysis included 135 patients (control group, 68 cases; TSD group, 67 cases). Primary and secondary outcome measures after 2 weeks of treatment showed no improvement (versus baseline) in both groups, with no differences between groups. At 12 weeks, QOL, physician VAS, patient VAS, ESR and CRP were improved in both groups, but MRSS and RP score were improved only in the TSD group (all P < 0.05). MRSS, RP score, QOL, physician VAS, patient VAS, ESR and CRP differed significantly between groups (all P < 0.05). Meanwhile, the overall treatment effect was significantly higher in the TSD group than in the control group (P < 0.05). Adverse events in the two groups were similar (P > 0.05). Bathing with TSD plus oral prednisone achieves better outcomes than oral prednisone alone in patients with dcSSc and is not associated with serious adverse events.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 32 条
  • [1] Chung L, 2012, CLIN EXP RHEUMATOL, V30, pS97
  • [2] Clements PJ, 1999, ARTHRITIS RHEUM-US, V42, P1194, DOI 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO
  • [3] 2-7
  • [4] Foocharoen Chingching, 2015, Journal of the Medical Association of Thailand, V98, P1082
  • [5] Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis
    Georges, C
    Chassany, O
    Mouthon, L
    Tiev, K
    Marjanovic, Z
    Meyer, O
    Toledano, C
    Ilie, D
    Guillevin, L
    Sereni, D
    Cabane, J
    Farge, D
    [J]. REVUE DE MEDECINE INTERNE, 2004, 25 (01): : 16 - 21
  • [6] The Pathogenesis of Systemic Sclerosis Revisited
    Geyer, Matthias
    Mueller-Ladner, Ulf
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2011, 40 (02) : 92 - 103
  • [7] Wenyang Huazhuo Tongluo formula, a Chinese herbal decoction, improves skin fibrosis by promoting apoptosis and inhibiting proliferation through down-regulation of survivin and cyclin D1 in systemic sclerosis
    Han, Li
    Bian, Hua
    Ouyang, Jingfeng
    Bi, Yuefeng
    Yang, Lei
    Ye, Songshan
    [J]. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, 16
  • [8] Health-Related Quality of Life in Systemic Sclerosis: A Systematic Review
    Hudson, Marie
    Thombs, Brett D.
    Steele, Russell
    Panopalis, Pantelis
    Newton, Evan
    Baron, Murray
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (08): : 1112 - 1120
  • [9] Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease
    Iudici, Michele
    Cuomo, Giovanna
    Vettori, Serena
    Avellino, Manuela
    Valentini, Gabriele
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11
  • [10] Khanna D, 2005, J RHEUMATOL, V32, P832